Anna Anatolievna Klimovich
◽
Olga Nikolaevna Styshova
◽
Alexander Mikhailovich Popov
◽
Tatiana Vladimirovna Moskvina
◽
Alexander Vasilevich Tsybulsky
◽
...
Background:
The researchers of PIBOC RAS developed the dermo-protective topical
drug called «Kourochitin», active substance of which is known quinazoline alkaloid tryptanthrin. In
the present work, therapeutic efficacy of this drug in the treatment of allergic dermatosis was evaluated.
Methods:
Dermo-protective action of «Kourochitin» was studied in tow murine models: 2, 4- dinitrofluorobenzene-
induced allergic contact dermatitis (ACD) and imiquimod-induced psoriasis.
Results and Discussion:
In a model ACD, it was shown that «Kourochitin» exhibits the curative
action on pathophysiological, hematological and immunological parameters in ACD. Namely,
«Kourochitin» 1) reduces the level of erythema in the allergen damaged skin area and increases the
healing index of the epidermis; 2) normalizes the content of eosinophils, basophils and monocytes in
the blood of experimental animals; 3) inhibits the production of main pro-inflammatory cytokines:
interleukins - 1 and 2, interferon-gamma, and granulocyte-macrophage colony-stimulating factor. In
a murine model of imiquimod-induced psoriasis, it was shown that «Kourochitin» application led to
reduction in psoriasis severity on the inflamed epidermis of experimental animals. Additionally, in
veterinary research, «Kourochitin»-treatment of canine atopic dermatitis almost completely eliminated
signs of allergic manifestations on the epidermis.
Conclusion:
The obtained data suggest that «Kourochitin» as anti-inflammatory, anti-allergic, and
wound healing remedy is a potential drug for therapy of various dermatological diseases, in particular
allergic skin lesions.
Protective action of KT2-962, a novel TXA2 receptor antagonist, against various brain injury models in experimental animals.
